What ResMed (RMD)’s Earnings Beat and Completed Buyback Means For Shareholders

• In late January 2026, ResMed reported past fiscal second-quarter results showing sales of US$1,422.81 million and net income of US$392.59 million, alongside a US$0.60 per-share quarterly dividend and completion of a long-running share repurchase program totaling US$1.19 billion.
• The combination of double-digit revenue and earnings per share growth, strong demand for masks and digital health software, and ongoing capital returns underscored management’s focus on both business expansion and shareholder payouts.
• Next, we’ll examine how this earnings beat, underpinned by strong mask and digital health demand, shapes ResMed’s broader investment narrative.

Outshine the giants: these 24 early-stage AI stocks could fund your retirement.

What Is ResMed’s Investment Narrative?

To own ResMed, you really need to believe in the durability of global sleep and respiratory care demand, plus the company’s ability to keep pairing devices and masks with higher-margin digital health software. The latest quarter’s revenue and earnings beat, backed by double-digit growth and strong mask and software demand, reinforces that core thesis rather than changing it. Short term, the key catalysts still look similar: uptake of newer masks and AI-enabled tools like Smart Comfort, execution on U.S. manufacturing expansion, and how efficiently ResMed converts this growth into cash for dividends and buybacks. The confirmed US$0.60 dividend and completion of the US$1.19 billion repurchase program support confidence in cash generation, but they also sharpen the main risk right now: any slowdown in mask resupply or digital health adoption could quickly pressure margins and limit future capital returns.

However, investors should also consider how dependent current optimism is on continued mask and software momentum.

ResMed’s shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

ResMed’s Simply Wall St Community fair values span roughly US$180 to just under US$300 across seven views, underlining how differently people see its upside, especially with masks and digital health now so central to near term execution and longer term business resilience.

Explore 7 other fair value estimates on ResMed – why the stock might be worth as much as 15% more than the current price!

Build Your Own ResMed Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes – extraordinary investment returns rarely come from following the herd.

• A great starting point for your ResMed research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free ResMed research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate ResMed’s overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don’t miss this chance:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com